Pre-eclampsia
From Ganfyd
Pre-eclampsia is the maternal gestational onset of hypertension and proteinuria.
Contents |
Clinical definition
A working definition is after 20 weeks of gestation:
- Hypertension -systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, or both (in women known to be previously normotensive)
- Proteinuria > 300 mg/24 hours
Severe Pre-eclampsia: EITHER
- Proteinuria > 5g/24 hours (or 3+ on dipstick)
- Hypertension - systolic > 160mmHg or diastolic > 110mmHg on 2 occasions
OR
- Protenuria > 5g/24 hours
- Hypertension - diastolic > 100mmHg
- 2 Further clinical symptoms or HELLP syndrome
Incidence
- 2-8% of first time pregnant mothers[1]
- Marked variation in different populations
- Higher in nulliparous than multiparous women
- Risk factors:
- Chronic hypertension
- Maternal age at first pregnancy (over 35 years)
- Nephropathy
- Thrombophilia
- Multiple gestation
- Previous preeclampsia in pregnancy
- Risk reduced by a third in smokers but with increased risk to fetus !
Aetiology
The cause is not fully understood but can be described as abnormal placentation with placental mediators targeting the maternal endothelium. There is defective invasion of trophoblast cells and remodelling of the uterine vasculature with reduced utero-placental perfusion and consequential placental ischaemia. There is activation of maternal vasoconstriction and damage of endothelial cells by several mechanisms including reactive oxygen species and defective synthesis of nitric oxide.
Associations
- Increased perinatal mortality
- Placental abruption
- HELLP syndrome (haemolysis, elevated liver enzymes, low platelets)
- Eclampsia
- Increased risk eclampsia
- Raised asymmetric dimethyl arginine, a competitive inhibitor of nitric oxide synthase
- Raised soluble fms-like tyrosine kinase 1 (soluble VEGFR-1 , vascular endothelial growth factor receptor-1)
- Raised soluble endoglin, which impairs activation of nitric oxide synthase mediated by transforming growth factor β
Clinical Features
Symptoms
Pre-eclampsia is often asymptomatic, and symptoms are often vague and non-specific. This rare condition is one reason why abdominal pain must be taken seriously in any pregnant woman. By definition, if pre-eclampsia progresses to convulsions, it is termed "eclampsia".
- Stridor (from laryngeal oedema)
- Dyspnoea (from pulmonary oedema)
- Headache
- Epigastric pain
- Right Upper Quadrant pain
- Peripheral Oedema
Signs
Cardiac
- Hypertension
- Increased sensitivity to catecholamines and vasopressors
- Increased Systemic Vascular Resistance
- Dissociation between Central Venous Pressure and *Pulmonary capillary Wedge Pressure
Respiratory
- Tachypnoea
- Desaturation
Renal
- Proteinuria > 300mg/24hrs
- Oliguria < 400ml/day
- High creatinine
- Plasma uric acid > 0.35
CNS
- Hyperreflexia
- Clonus
- May progress to eclampsia
Fetus
- Intrauterine growth retardation
- Oligohydramnios
Particular features of severe pre-eclampsia
- BP 160/110
- proteinuria 5g/24hrs
- oliguria < 400ml/24hrs
- pulmonary oedema
- cerebrovascular haemorrhage, or cerebral oedema
- epigastric/RUQ pain
- hepatic rupture
- platelets < 100 x10^9/litre
Prevention
- Low dose aspirin
- Decreases the risk of recurrence of preeclampsia by 10%, of prematurity by 8% and of perinatal mortality by 14%.
- Calcium supplements in third word population
- Possibly L-arginine with vitamins[2]
- Antioxidant vitamins do not work[3][4]
Treatment
- Hypotensive agents
- Magnesium sulfate in severe pre-eclampsia prevents eclampsia[5] and has good long term safety data[6]
Also see Eclampsia
References
- ↑ Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in perinatology. 2009 Jun; 33(3):130-7.(Link to article – subscription may be required.)
- ↑ Vadillo-Ortega F, Perichart-Perera O, Espino S, Avila-Vergara MA, Ibarra I, Ahued R, Godines M, Parry S, Macones G, Strauss JF. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ (Clinical research ed.). 2011; 342:d2901.(Epub)
- ↑ Xu H, Perez-Cuevas R, Xiong X, Reyes H, Roy C, Julien P, Smith G, von Dadelszen P, Leduc L, Audibert F, Moutquin JM, Piedboeuf B, Shatenstein B, Parra-Cabrera S, Choquette P, Winsor S, Wood S, Benjamin A, Walker M, Helewa M, Dubé J, Tawagi G, Seaward G, Ohlsson A, Magee LA, Olatunbosun F, Gratton R, Shear R, Demianczuk N, Collet JP, Wei S, Fraser WD. An international trial of antioxidants in the prevention of preeclampsia (INTAPP). American journal of obstetrics and gynecology. 2010 Mar; 202(3):239.e1-239.e10.(Link to article – subscription may be required.)
- ↑ Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, Pearson GD, Wapner RJ, Varner MW, Thorp JM, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Smith WJ, Saade G, Sorokin Y, Anderson GB. Vitamins C and E to prevent complications of pregnancy-associated hypertension. The New England journal of medicine. 2010 Apr 8; 362(14):1282-91.(Link to article – subscription may be required.)
- ↑ Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002 Jun 1; 359(9321):1877-90.
- ↑ The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG : an international journal of obstetrics and gynaecology. 2007 Mar; 114(3):300-9.(Link to article – subscription may be required.)
This article is a work in progress. Please feel free to contribute to it.